Apexigen successfully listed on Nasdaq!
Date: 2022-08-01

Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of Nasdaq successfully and presented in stock code “APGN” this evening, August 1st, Beijing time. 

In July 2018, Efung Capital was one of the players of Apexigen's Series C financing.

Headquartered in San Carlos, CA, Apexigen is a clinical-stage biopharmaceutical company. It focuses on inventing the new generations of antibodies that target on cancer immunotherapies. The Corporation possesses a distinctive antibody drug development platform, APXiMAB, which is currently being developed for its core product-APX005M- additional with pre-clinical programs.

The development platform enables the firm and its partners to foster high quality antibodies against plentiful targets, even those that are difficult to develop into drugs using traditional antibody elaboration techniques. Among all antibodies, seven of them using APXiMAB have already entered the clinical phase.

The current major product of Apexigen Corporations, APX005M, is a tumor immunotherapy antibody targeting CD40, which is currently in multiple Phase II clinical trials for a variety of symptoms.

Pai Zhu, the managing partner of Efung Capital, mentioned that Apexigen Company had an experienced management team and a promising pipeline. In the light of that, APX005M was the leading player in the global drug development. As we acclaim its listing on Nasdaq, we hope that Apexigen will continue to innovate and develop more ground-breaking products.

In the future, Efung Capital will continue to conduct research such as cell therapy, gene treatment, immunotherapy, and other emerging investment tracks. At the same time, the firm will continue to invest in innovative medical technology, and promote the industrialization of biomedical technology.

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务